Select Publications


Fowler N et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: Results from a Phase I study. Proc ASH 2010;Abstract 964.


Hagenbeek A et al. 90Y-ibritumomab tiuxetan (Zevalin®) consolidation of first remission in advanced-stage follicular non-Hodgkin’s lymphoma: Updated results after a median follow-up of 66.2 months from the international, randomized, phase III First-Line Indolent Trial (FIT) in 414 patients. Proc ASH 2010;Abstract 594.


A phase II study of VcR-CVAD with rituximab maintenance for untreated mantle cell lymphoma. NC00433537.

A randomized phase II trial of maintenance vs consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma. NCT00310037.

Bendamustine hydrochloride and rituximab with or without bortezomib followed by rituximab with or without lenalidomide in treating patients with high-risk stage II, stage III, or stage IV follicular lymphoma. NCT01216683.

Phase III trial of combined immunochemotherapy with FCR versus BR in previously untreated CLL. NCT00769522.


Rituximab in treating patients with low tumor burden indolent non-Hodgkin’s lymphoma. NCT00075946.